Literature DB >> 17963725

Selective modulation of promoter recruitment and transcriptional activity of PPARgamma.

Dorothy D Sears1, Albert Hsiao, Jachelle M Ofrecio, Justin Chapman, Weimin He, Jerrold M Olefsky.   

Abstract

Peroxisome proliferator-activated receptor gamma (PPARgamma) is a nuclear receptor regulated by the insulin-sensitizing thiazolidinediones (TZDs). We studied selective modulation of endogenous genes by PPARgamma ligands using microarray, RNA expression kinetics, and chromatin immunoprecipitation (ChIP) in 3T3-L1 adipocytes. We found over 300 genes that were significantly regulated the TZDs pioglitazone, rosiglitazone, and troglitazone. TZD-mediated expression profiles were unique but overlapping. Ninety-one genes were commonly regulated by all three ligands. TZD time course and dose-response studies revealed gene- and TZD-specific expression kinetics. PEPCK expression was induced rapidly but PDK4 expression was induced gradually. Troglitazone EC50 values for PEPCK, PDK4, and RGS2 regulation were greater than those for pioglitazone and rosiglitazone. TZDs differentially induced histone acetylation of and PPARgamma recruitment to target gene promoters. Selective modulation of PPARgamma by TZDs resulted in distinct expression profiles and transcription kinetics which may be due to differential promoter activation and chromatin remodeling of target genes.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17963725      PMCID: PMC2585742          DOI: 10.1016/j.bbrc.2007.10.057

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  30 in total

Review 1.  Treatment of insulin resistance with peroxisome proliferator-activated receptor gamma agonists.

Authors:  J M Olefsky
Journal:  J Clin Invest       Date:  2000-08       Impact factor: 14.808

2.  Peroxisome proliferator-activated receptor-gamma ligands inhibit adipocyte 11beta -hydroxysteroid dehydrogenase type 1 expression and activity.

Authors:  J Berger; M Tanen; A Elbrecht; A Hermanowski-Vosatka; D E Moller; S D Wright; R Thieringer
Journal:  J Biol Chem       Date:  2001-01-22       Impact factor: 5.157

3.  Activation of human peroxisome proliferator-activated receptor (PPAR) subtypes by pioglitazone.

Authors:  J Sakamoto; H Kimura; S Moriyama; H Odaka; Y Momose; Y Sugiyama; H Sawada
Journal:  Biochem Biophys Res Commun       Date:  2000-11-30       Impact factor: 3.575

Review 4.  Controlling nuclear receptors: the circular logic of cofactor cycles.

Authors:  Valentina Perissi; Michael G Rosenfeld
Journal:  Nat Rev Mol Cell Biol       Date:  2005-07       Impact factor: 94.444

5.  Degradation of the peroxisome proliferator-activated receptor gamma is linked to ligand-dependent activation.

Authors:  S Hauser; G Adelmant; P Sarraf; H M Wright; E Mueller; B M Spiegelman
Journal:  J Biol Chem       Date:  2000-06-16       Impact factor: 5.157

6.  A novel potent antagonist of peroxisome proliferator-activated receptor gamma blocks adipocyte differentiation but does not revert the phenotype of terminally differentiated adipocytes.

Authors:  H S Camp; A Chaudhry; T Leff
Journal:  Endocrinology       Date:  2001-07       Impact factor: 4.736

7.  A unique PPARgamma ligand with potent insulin-sensitizing yet weak adipogenic activity.

Authors:  S Rocchi; F Picard; J Vamecq; L Gelman; N Potier; D Zeyer; L Dubuquoy; P Bac; M F Champy; K D Plunket; L M Leesnitzer; S G Blanchard; P Desreumaux; D Moras; J P Renaud; J Auwerx
Journal:  Mol Cell       Date:  2001-10       Impact factor: 17.970

8.  A synthetic triterpenoid, 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid (CDDO), is a ligand for the peroxisome proliferator-activated receptor gamma.

Authors:  Y Wang; W W Porter; N Suh; T Honda; G W Gribble; L M Leesnitzer; K D Plunket; D J Mangelsdorf; S G Blanchard; T M Willson; M B Sporn
Journal:  Mol Endocrinol       Date:  2000-10

Review 9.  PPAR gamma and the treatment of insulin resistance.

Authors:  J M Olefsky; A R Saltiel
Journal:  Trends Endocrinol Metab       Date:  2000-11       Impact factor: 12.015

10.  Comprehensive messenger ribonucleic acid profiling reveals that peroxisome proliferator-activated receptor gamma activation has coordinate effects on gene expression in multiple insulin-sensitive tissues.

Authors:  J M Way; W W Harrington; K K Brown; W K Gottschalk; S S Sundseth; T A Mansfield; R K Ramachandran; T M Willson; S A Kliewer
Journal:  Endocrinology       Date:  2001-03       Impact factor: 4.736

View more
  34 in total

1.  The role of peroxisome proliferator-activated receptor γ in pancreatic β cell function and survival: therapeutic implications for the treatment of type 2 diabetes mellitus.

Authors:  D Gupta; T Kono; C Evans-Molina
Journal:  Diabetes Obes Metab       Date:  2010-12       Impact factor: 6.577

2.  Comparisons of differential gene expression elicited by TCDD, PCB126, βNF, or ICZ in mouse hepatoma Hepa1c1c7 cells and C57BL/6 mouse liver.

Authors:  Rance Nault; Agnes L Forgacs; Edward Dere; Timothy R Zacharewski
Journal:  Toxicol Lett       Date:  2013-08-29       Impact factor: 4.372

3.  Identical gene regulation patterns of T3 and selective thyroid hormone receptor modulator GC-1.

Authors:  Chaoshen Yuan; Jean Z H Lin; Douglas H Sieglaff; Steven D Ayers; Frances Denoto-Reynolds; John D Baxter; Paul Webb
Journal:  Endocrinology       Date:  2011-11-08       Impact factor: 4.736

Review 4.  Allosteric pathways in nuclear receptors - Potential targets for drug design.

Authors:  Elias J Fernandez
Journal:  Pharmacol Ther       Date:  2017-10-31       Impact factor: 12.310

5.  Additional sex comb-like (ASXL) proteins 1 and 2 play opposite roles in adipogenesis via reciprocal regulation of peroxisome proliferator-activated receptor {gamma}.

Authors:  Ui-Hyun Park; Seung Kew Yoon; Taesun Park; Eun-Joo Kim; Soo-Jong Um
Journal:  J Biol Chem       Date:  2010-11-03       Impact factor: 5.157

6.  Molecular Characterization of the Tumor Suppressor Candidate 5 Gene: Regulation by PPARgamma and Identification of TUSC5 Coding Variants in Lean and Obese Humans.

Authors:  Trina A Knotts; Hyun Woo Lee; Jae Bum Kim; Pieter J Oort; Ruth McPherson; Robert Dent; Keisuke Tachibana; Takefumi Doi; Songtao Yu; Janardan K Reddy; Kenji Uno; Hideki Katagiri; Magdalena Pasarica; Steven R Smith; Dorothy D Sears; Michel Grino; Sean H Adams
Journal:  PPAR Res       Date:  2010-03-01       Impact factor: 4.964

7.  Peroxisome proliferator-activated receptor gamma activation restores islet function in diabetic mice through reduction of endoplasmic reticulum stress and maintenance of euchromatin structure.

Authors:  Carmella Evans-Molina; Reiesha D Robbins; Tatsuyoshi Kono; Sarah A Tersey; George L Vestermark; Craig S Nunemaker; James C Garmey; Tye G Deering; Susanna R Keller; Bernhard Maier; Raghavendra G Mirmira
Journal:  Mol Cell Biol       Date:  2009-02-23       Impact factor: 4.272

8.  PPARgamma and C/EBP factors orchestrate adipocyte biology via adjacent binding on a genome-wide scale.

Authors:  Martina I Lefterova; Yong Zhang; David J Steger; Michael Schupp; Jonathan Schug; Ana Cristancho; Dan Feng; David Zhuo; Christian J Stoeckert; X Shirley Liu; Mitchell A Lazar
Journal:  Genes Dev       Date:  2008-11-01       Impact factor: 11.361

9.  Thiazolidinediones and cardiovascular risk - a question of balance.

Authors:  Erland Erdmann; Bernard Charbonnel; Robert Wilcox
Journal:  Curr Cardiol Rev       Date:  2009-08

10.  Rosiglitazone treatment reduces diabetic neuropathy in streptozotocin-treated DBA/2J mice.

Authors:  Timothy D Wiggin; Matthias Kretzler; Subramaniam Pennathur; Kelli A Sullivan; Frank C Brosius; Eva L Feldman
Journal:  Endocrinology       Date:  2008-06-26       Impact factor: 4.736

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.